Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaoer Ma-Long-Zhi-Ke-Ping-Chuan Granules
- Development stage
- Unknown
- Lead developer
- Hainan Huluwa Pharmaceutical Group
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Xiaoer Ma-Long-Zhi-Ke-Ping-Chuan Granules is a traditional Chinese medicine (TCM) herbal formulation developed for the treatment of cough variant asthma (CVA) in children, specifically those presenting with the phlegm-heat retention of the lung syndrome pattern. Derived from the classical TCM formulas Maxing Shigan Decoction and Dingchuan Decoction, the granules contain active components such as ephedrine, amygdalin, and forsythoside A. The formulation exhibits antitussive, antiasthmatic, expectorant, and antiallergic properties. Originally based on an empirical prescription from the First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, the drug is being co-developed by Shanghai Municipal Hospital of Traditional Chinese Medicine and Hainan Huluwa Pharmaceutical Group, and has progressed to Phase III clinical trials in China.
- Other names
- Xiaoer Ma Long Zhi Ke Ping Chuan GranuleXiaoer Malong Zhike Pingchuan Granules小儿麻龙止咳平喘颗粒
02
Targets
IL-6 (Interleukin 6)
Beyond the preview
Go deeper on Xiaoer Ma-Long-Zhi-Ke-Ping-Chuan Granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xiaoer Ma-Long-Zhi-Ke-Ping-Chuan Granules.